|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
<i>Conclusions.</i> Although the number of patients analysed was limited, we found that the addition of cetuximab significantly improves the outcomes in KRAS wild type patients with unresectable colorectal cancer liver-confined metastases.
|
28167959 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
10-fold) only in metastases induced by one out of 3 metastatic hybrids tested; (2) to the transcription level of c-Ha-ras and c-Ki-ras genes which was enhanced (approx.
|
1309725 |
1992 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
K-Ras, B-Raf and p53 mutations were detected in 27, 3 and 32% of the cases, with K-Ras mutations significantly associated with metastatic tumour (P=0.019).
|
16969349 |
2006 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
K-ras-2 amplification was observed in 3 high-grade tumors from 3 patients with metastases.
|
2071229 |
1991 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutation seems to be associated with metastasis in specific sites, lung and brain, in colorectal cancer patients.
|
21239505 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS and EGFR mutation status was different between primary tumors and corresponding metastases in 6 (7.5%) and 7 (8.75%) patients, respectively.
|
21414214 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutations were significantly associated with usual adenocarcinoma morphology (multivariate P=0.014), peritumoral lymphocytic response (χ2, P=0.028; multivariate P=0.017), T3-T4 status (χ2, P=0.012; multivariate P=0.015), right-sided location (multivariate P=0.027), absence of lymphovascular invasion (multivariate P=0.008), and metastases at the time of resection (multivariate P=0.034).
|
23090042 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutation was detected in 3 of 14 cases (21%) including 1 primary and 2 metastatic tumors.
|
23495083 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population.
|
23573237 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutations were associated with lung-only metastases (P = 2.3 × 10(-4)), BRAF mutations with peritoneal (P = 9.2 × 10(-4)) and nodal-only (P = 3.7 × 10(-5)) metastases, and MSI (BRAF(WT)) with nodal-only metastases (P = 2.9 × 10(-4)).
|
23741067 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
|
23887294 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
K-Ras mutation activates CSCs, contributing to colorectal tumorigenesis and metastasis in CRC cells harboring APC mutations.
|
24491301 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS oncogene testing is recommended in all patients with metastatic colorectal cancer due to its impact on treatment selection, but we do not know if KRAS genotype affects extent or pattern of metastases.
|
24906690 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
|
25155157 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutation rates increased significantly from primary tumors to lymph node metastases and distant metastases within the neuroendocrine negative CRC group (44%, 53%, 64%, respectively, P = 0.042).
|
25337237 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS-mutant NSCLC patients with concurrent LKB1 loss had a higher number of metastatic sites at the time of diagnosis (median 2.5 vs. 2, P = 0.01), higher incidence of extrathoracic metastases (P = 0.01), and developed brain metastasis more frequently (48% vs. 25%, P = 0.02).
|
25737507 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
KRAS-mutated carcinomas were more frequently observed in female patients (47.5% vs 37.1%, p = 0.005) and mucinous differentiation (34.7% vs 24.8%, p = 0.004), but have no difference between lymph node (LN) metastases and among pTNM stages.
|
25929517 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutation was found in 15 (25.9 %) primary tumors and 18 (31.0 %) metastases.
|
27270901 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
KRAS activation occurring in more than 90% of pancreatic ductal adenocarcinomas (PDAC) drives progression and metastasis, but the underlying mechanisms involved in these processes are still poorly understood.
|
27793842 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS, PIK3CA and TP53 mutations were associated with distant metastases and a poor prognosis.
|
30867754 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
KRAS and GNAS are frequently altered in low-grade AMTs, while TP53 is frequently altered in high-grade AMTs, with no apparent change in expression between primary and metastatic tumors.
|
31583543 |
2020 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
A KRAS mutation was found in 38 (38.4%) primary tumors and in 36 (36.4%) related metastases.
|
19056857 |
2008 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
A bone marrow aspirate sampled at the site of progressing metastasis in the right iliac bone was performed, and single cell molecular analysis using array-CGH of Epithelial Specific Antigen (ESA)-positive metastatic cells, and revealed two distinct regions of amplification, 12p12.1 and 17q12-q21.2 amplicons, containing the KRAS (12p) and ERBB2 (HER2/NEU) (17q) oncogenes.
|
22014070 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
A multivariate model adjusted for age at diagnosis, site of origin of tumor tissue (primary vs metastases), referral center, number of metastatic sites, and first-line chemotherapy backbone, showed that K-Ras mutation rate remained a significant predictor of PFS and OS in the whole population.
|
26384309 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
A thousand and eighteen cases (879 primary tumors and 139 metastases) of metastatic colorectal cancer were analyzed for the KRAS mutational status of codons 12 and 13 of the KRAS gene by genomic sequencing in a routine setting.
|
19679400 |
2009 |